Patients with rheumatoid arthritis treated with methotrexate (MTX): Concentrations of steady-state erythrocyte MTX correlate to plasma concentrations and clinical efficacy

Journal of Rheumatology

Volumn 35, Issue 9, 2008, Pages 1709-1715

  Hornung, Nete ^a   Ellingsen, Torkell ^b   Attermann, Jørn ^c   Stengaard Pedersen, Kristian ^b   Poulsen, Jørgen Hjelm ^d  

^a RANDERS REGIONAL HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

^d HVIDOVRE HOSPITAL   (Denmark)

Author keywords

Erythrocyte; Methotrexate; Pharmacokinetics; Rheumatoid arthritis; Treatment efficacy

Indexed keywords

METHOTREXATE;

AREA UNDER THE CURVE; ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; ERYTHROCYTE; FLU LIKE SYNDROME; HAIR LOSS; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MONOTHERAPY; MOUTH ULCER; NAUSEA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RHEUMATOID ARTHRITIS; STEADY STATE; STOMATITIS;

ANTIRHEUMATIC AGENTS; AREA UNDER CURVE; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROCYTES; FEMALE; HEALTH STATUS; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; MODELS, BIOLOGICAL; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 54049158589     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Tugwell P, Bennet K, Gent M. Methotrexate in rheumatoid arthritis. Indications, contraindications, efficacy and safety. Ann Intern Med 1987;107:358-66.
2. Weinblatt ME, Maier AL, Fraser PA, et al. Longterm prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy. J Rheumatol 1998;25:238-42.
3. Case JP. Old and new drugs used in rheumatoid arthritis: a historical perspective. Part 1: the older drugs. Am J Ther 2001;8:123-43.
4. O'Dell JR. Methotrexate use in rheumatoid arthritis. Rheum Dis Clin North Am 1997;23:779-96.
5. Wluka A, Buchbinder R, Mylvaganam A, et al. Longterm methotrexate use in rheumatoid arthritis: 12 year followup of 460 patients treated in community practice. J Rheumatol 2000;27:1864-71.
6. Hoekstra M, van de Laar MA, Bernelot Moens HJ, et al. Longterm observational study of methotrexate use in a Dutch cohort of 1022 patients with rheumatoid arthritis. J Rheumatol 2003;30:2325-9.
7. Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 2005;57:163-72.
8. Chabner BA, Allegra CJ, Curt GA, et al. Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest 1985;76:907-12.
9. Kremer JM. Toward a better understanding of methotrexate. Arthritis Rheum 2004;50:1370-82.
10. Kremer JM. The mechanism of action of methotrexate in rheumatoid arthritis: the search continues. J Rheumatol 1994;21:1-5.
11. Van Ede AE, Laan RFJM, Blom HJ, et al. Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum 1998;27:277-92.
12. Chan ES, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002;4:266-73.
13. Cronstein BN. The mechanism of action of methotrexate. Rheum Dis Clin North Am 1997;23:739-55.
14. Dolezalova P, Krijt J, Chladek J, et al. Adenosine and methotrexate polyglutamate concentrations in patients with juvenile arthritis. Rheumatology Oxford 2005;44:74-9.
15. Morabito L, Montesinos MC, Schreibman DM, et al. Methotrexate and sulfasalazine promotes adenosine release by a mechanism that requires ecto'-5'-nucleotidase-mediated conversion of adenosine nucleotides. J Clin Invest 1998;101:295-300.
16. Bannwarth B, Pehourcq F, Schaeverbeke T, et al. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet 1996;30:194-210.
17. Seideman P. Methotrexate - the relationship between dose and clinical effect. Arthritis Rheum 1994;37:830-3.
18. Kamen BA, Nylen PA, Camitta BM, et al. Methotrexate accumulation and folate depletion in cells as a possible mechanism of chronic toxicity to the drug. Br J Haematol 1981;49:355-60.
19. Angelis-Stoforidis P, Vajda FJ, Christophidis N. Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis. Clin Exp Rheumatol 1999;17:313-20.
20. Dervieux T, Furst D, Lein DO, et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 2004;50:2766-74.
21. Fathi NH, Mitros F, Hoffman J, et al. Longitudinal measurement of methotrexate liver concentrations does not correlate with liver damage, clinical efficacy, or toxicity during a 3.5 year double blind study in rheumatoid arthritis. J Rheumatol 2002;29:2092-8.
22. Duby S, Karsh J, Prchal JF, et al. Measurements of red blood cell methotrexate concentrations and lymphocyte subsets during therapy of rheumatoid arthritis. Clin Exp Rheumatol 1985;3:5-9.
23. Kristensen K, Nielsen S, Karup Pedersen F, et al. Erythrocyte- methotrexate and disease activity in children treated with oral methotrexate for juvenile chronic arthritis. Scand J Rheumatol 2000;29:187-9.
24. Dervieux T, Furst D, Lein DO, et al. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study. Ann Rheum Dis 2005;64:1180-5.
25. Dervieux T, Greenstein N, Kremer J. Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum 2006;54:3095-103.
26. Edelman J, Biggs DF, Jamali F, et al. Low-dose methotrexate kinetics in arthritis. Clin Pharmacol Ther 1984;35:382-6.
27. Herman RA, Vengpedersen P, Hoffman J, et al. Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients. J Pharm Sci 1989;78:165-71.
28. Sinnet MJ, Groff GD, Raddatz DA, et al. Methotrexate pharamcokinetics in patients with rheumatoid arthritis. J Rheumatol 1989;16:745-8.
29. Brooks PJ, Spruill WJ, Parish RC, et al. Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis. Arthritis Rheum 1990;33:91-4.
30. Tracy TS, Krohn K, Jones DR, et al. The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis. Eur J Clin Pharmacol 1992;42:121-5.
31. Tracy TS, Worster T, Bradley JD, et al. Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis. Br J Clin Pharmacol 1994;37:453-6.
32. Kremer JM, Petrillo GF, Hamilton RA. Pharmacokinetics and renal function in patients with rheumatoid arthritis receiving a standard dose of oral weekly methotrexate: association with significant decreases in creatinine clearance and renal clearance of the drug after 6 months of therapy. J Rheumatol 1995;22:38-40.
33. Kremer JM, Petrillo GF, Hamilton RA. Examination of pharmacokinetic variables in a cohort of patients with rheumatoid arthritis beginning therapy with methotrexate compared with a cohort receiving the drug for a mean of 81 months. J Rheumatol 1995;22:41-4.
34. Godfrey C, Sweeney K, Miller K, et al. The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis. Br J Clin Pharmacol 1998;46:369-76.
35. Hiraga Y, Yuhki Y, Itoh K, Tadano K, Takahashi Y, Mukai M. Pharmacokinetics and efficacy of low-dose methotrexate in patients with rheumatoid arthritis. Mod Rheumatol 2004;14:135-42.
36. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
37. Seideman P, Beck O, Eksborg S, et al. The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis. Br J Clin Pharmacol 1993;35:409-12.
38. Scully CJ, Anderson CJ, Cannon GW. Long-term methotrexate therapy for rheumatoid arthritis. Semin Arthritis Rheum 1991;20:317-31.
39. Weinblatt ME. Efficacy of methotrexate in rheumatoid arthritis. Br J Rheumatol 1995;34 Suppl 2:43-8.
40. Wolfe F. Adverse drug reactions of DMARDs and DC-ARTs in rheumatoid arthritis. Clin Exp Rheumatol 1997;15 Suppl 17:S75-81.
41. Ortendahl M, Schettler JD, Fries JF. Factors influencing length of time taking methotrexate in rheumatoid arthritis. J Rheumatol 2000;27:1139-47.
42. Skeith KJ, Russell AS, Jamali F, et al. Lack of significant interaction between low dose methotrexate and ibuprofen or flurbiprofen in patients with arthritis. J Rheumatol 1990;17:1008-10.
43. Stewart CF, Fleming RA, Arkin CR, et al. Coadministration of naproxen and low-dose methotrexate in patients with rheumatoid arthritis. Clin Pharmacol Ther 1990;47:540-6.
44. Ahern M, Booth J, Loxton A, et al. Methotrexate kinetics in rheumatoid arthritis: is there an interaction with nonsteroidal antiinflammatory drugs? J Rheumatol 1988;15:1356-60.
45. Wiela-Hojenska A, Orzechowska-Juzwenko K, Swierkot J, et al. Monitoring methotrexate therapy in patients with rheumatoid arthritis. Int J Clin Pharmacol Ther 2004;42:434-41.
46. Lafforgue P, Monjanel-Mouterde S, Durand A, et al. Lack of correlation between pharmacokinetics and efficacy of low dose methotrexate in patients with rheumatoid arthritis. J Rheumatol 1995;22:844-9.
47. Bologna C, Anaya JM, Bressolle F, et al. Correlation between methotrexate pharmacokinetic parameters, and clinical and biological status in rheumatoid arthritis patients. Clin Exp Rheumatol 1995;13:465-70.
48. Eksborg S, Albertioni F, Beck O, Peterson C, Seideman P. Methotrexate in rheumatoid arthritis - a limited sampling strategy for estimation of the area under the plasma concentration versus time curve. Ther Drug Monit 1994;16:560-3.